Cargando…

Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients’ Quality of Life: a Prospective, Non-interventional Trial

INTRODUCTION: Chronic spontaneous urticaria (CSU) is a common and hard to treat condition associated with a substantial negative impact on patients’ quality of life (QoL). Clinical studies have shown that rupatadine is effective and safe in the treatment of CSU, but data from routine clinical care a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metz, Martin, Weller, Karsten, Neumeister, Claudia, Izquierdo, Iñaki, Bödeker, Rolf-Hasso, Schwantes, Ulrich, Maurer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674450/ https://www.ncbi.nlm.nih.gov/pubmed/26591001 http://dx.doi.org/10.1007/s13555-015-0089-y

Ejemplares similares

O10 - Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2-11 years old)
por: Potter, Paul, et al.
Publicado: (2014)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria – Results from the validation of the Polish Urticaria Control Test()
por: Brzoza, Zenon, et al.
Publicado: (2022)

Rupatadine
por: Kaur, Manpreet, et al.
Publicado: (2013)

Looking forward to new targeted treatments for chronic spontaneous urticaria
por: Kocatürk, Emek, et al.
Publicado: (2017)

Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria
por: Kocatürk, Emek, et al.
Publicado: (2017)

Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria
por: Kocatürk, Emek, et al.
Publicado: (2019)

Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence
por: Bödeker, Rolf-Hasso, et al.
Publicado: (2010)

Management of chronic spontaneous urticaria: a worldwide perspective
por: Kolkhir, Pavel, et al.
Publicado: (2018)

Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study
por: Santamaria, Eva, et al.
Publicado: (2021)

Comparison of Efficacy, Safety and Cost-effectiveness of Rupatadine and Olopatadine in Patients of Chronic Spontaneous Urticaria: A Randomized, Double-blind, Comparative, Parallel Group Trial
por: Dakhale, Ganesh N, et al.
Publicado: (2016)

Population pharmacokinetic modelling of rupatadine solution in 6–11 year olds and optimisation of the experimental design in younger children
por: Santamaría, Eva, et al.
Publicado: (2017)

Chronic urticaria in most patients is poorly controlled: Results of the development, validation, and real life application of the arabic urticaria control test
por: Irani, Carla, et al.
Publicado: (2017)

Loratadine vs Rupatadine: Unearthing the Capital Choice in Chronic Idiopathic Urticaria (CIU) – A Randomized Controlled Trial
por: Fayaz, Syed H, et al.
Publicado: (2021)

In Chronic Spontaneous Urticaria, Comorbid Depression Linked to Higher Disease Activity, and Substance P Levels
por: Memet, Bachar, et al.
Publicado: (2021)

Rupatadine oral solution for 2–5-year-old children with allergic rhinitis: a safety, open-label, prospective study
por: Santamaría, Eva, et al.
Publicado: (2018)

Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know
por: Terhorst-Molawi, Dorothea, et al.
Publicado: (2023)

Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis
por: Mullol, Joaquim, et al.
Publicado: (2019)

Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data
por: Staubach, P., et al.
Publicado: (2017)

A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria
por: Puhl, Viktoria, et al.
Publicado: (2021)

Rupatadine oral solution improves rhino-conjunctive symptoms control in children with 6-11 years weighing ≥25 kg with persistent allergic rhinitis
por: Izquierdo, Iñaki, et al.
Publicado: (2013)

Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT)
por: Kulthanan, Kanokvalai, et al.
Publicado: (2016)

IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?
por: Altrichter, Sabine, et al.
Publicado: (2011)

H(1)-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study
por: Weller, Karsten, et al.
Publicado: (2011)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

PD39 - Application of population pharmacokinetic modeling and simulation in the design of the optimal dose regime of rupatadine in children 2-5 year old children
por: Valle, Marta, et al.
Publicado: (2014)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial
por: Marmouz, Farid, et al.
Publicado: (2011)

Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial
por: Täubel, Jörg, et al.
Publicado: (2016)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria
por: Lakin, Elisa, et al.
Publicado: (2019)

Association of Chronic Urticaria with Psychological Distress: A Multicentre Cross-sectional Study
por: TAWIL, Samah, et al.
Publicado: (2023)

STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria
por: Sauer, Merle, et al.
Publicado: (2022)

Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries
por: Altrichter, Sabine, et al.
Publicado: (2022)

In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
por: Moñino‐Romero, Sherezade, et al.
Publicado: (2023)

Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity
por: Sauer, Merle, et al.
Publicado: (2021)

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
por: Weller, Karsten, et al.
Publicado: (2015)

Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
por: Kolkhir, Pavel, et al.
Publicado: (2021)

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()
por: Metz, Martin, et al.
Publicado: (2022)

Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador
por: Cherrez, A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ntev87u5usd2i6bob1d2qmtr71